PDCD1 and cancer: Anti‐PD‐1 agents reduce dormant DCCs in the lungs of mice [321], suggesting that PD‐1/PD‐L1 inhibitors may be effective in eliminating dormant cancer cells and preventing tumor relapse [344, 345].